• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用P-PHARM软件包进行群体药代动力学及最佳给药方案的条件评估。

Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.

作者信息

Gomeni R, Pineau G, Mentré F

机构信息

SIMED, Créteil, France.

出版信息

Anticancer Res. 1994 Nov-Dec;14(6A):2321-6.

PMID:7825966
Abstract

The adjustment of individual dosage regimen is an adaptive control process based upon an individual response to a pharmacokinetic model. To attain this objective, it is very helpful to know the characteristics of the population to which the subject belongs, in terms of mean parameters and interindividual variability. Usually the available information consists of incomplete and sparse data. For this reason it is essential to employ a computational methodology based on non-linear mixed-effect procedures in order to obtain a population parameter estimate. A Bayesian methodology can then be applied from the population parameters to the specific data for the individual requiring a dosage adjustment (such data includes drug concentration(s) of the active drug, demographic data, etc). The result of the Bayesian calculation supplies the required individual pharmacokinetic parameters. An optimal dosage regimen can be defined on the basis of therapeutical criteria (concentration ranges) as well as practical constraints such as: the size of available unitary drug dosages, feasible drug intake times, penalties associated with expected concentrations falling outside the therapeutic concentration ranges. In this paper we present the methodology and results obtained using the P-Pharm software tool. P-Pharm implements a non-linear mixed-effect population parameter estimation algorithm based on the EM algorithm. This method allows the inclusion of explicit variables into the calculations, it implements an individual Bayesian parameter estimation procedure and also an algorithm for the conditional assessment of the optimal dosage regimen given a list of practical constraints.

摘要

个体给药方案的调整是一个基于个体对药代动力学模型反应的自适应控制过程。为实现这一目标,了解个体所属人群在平均参数和个体间变异性方面的特征非常有帮助。通常,可用信息由不完整和稀疏的数据组成。因此,采用基于非线性混合效应程序的计算方法来获得群体参数估计至关重要。然后可以将贝叶斯方法从群体参数应用于需要调整剂量的个体的特定数据(此类数据包括活性药物的药物浓度、人口统计学数据等)。贝叶斯计算的结果提供所需的个体药代动力学参数。可以根据治疗标准(浓度范围)以及实际限制来定义最佳给药方案,例如:可用单一药物剂量的大小、可行的药物服用时间、与预期浓度超出治疗浓度范围相关的惩罚。在本文中,我们展示了使用P-Pharm软件工具获得的方法和结果。P-Pharm实现了基于期望最大化(EM)算法的非线性混合效应群体参数估计算法。该方法允许在计算中纳入显式变量,实现个体贝叶斯参数估计程序以及在给定一系列实际限制的情况下对最佳给药方案进行条件评估的算法。

相似文献

1
Population kinetics and conditional assessment of the optimal dosage regimen using the P-PHARM software package.使用P-PHARM软件包进行群体药代动力学及最佳给药方案的条件评估。
Anticancer Res. 1994 Nov-Dec;14(6A):2321-6.
2
Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage.利用常规血清监测数据对癫痫患者丙戊酸药代动力学进行非参数群体建模:对剂量的影响
J Clin Pharm Ther. 2004 Apr;29(2):105-20. doi: 10.1111/j.1365-2710.2003.00538.x.
3
Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.两种群体药代动力学程序NONMEM和P-PHARM用于他克莫司的比较。
Eur J Clin Pharmacol. 2002 Dec;58(9):597-605. doi: 10.1007/s00228-002-0517-7. Epub 2002 Nov 15.
4
Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.个体化药物给药方案:群体药代动力学和动力学模型、贝叶斯拟合及自适应控制的作用
Ther Drug Monit. 1993 Oct;15(5):380-93.
5
Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting.使用最大后验概率贝叶斯拟合对药物剂量方案进行自适应控制。
Int J Clin Pharmacol Ther. 1995 Oct;33(10):531-6.
6
A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.一种用于估计甲型血友病患者凝血因子 VIII 个体药代动力学参数的有限采样策略。
Ther Drug Monit. 2007 Feb;29(1):20-6. doi: 10.1097/FTD.0b013e3180311384.
7
A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.一种用于非线性混合效应模型估计的两步迭代算法及其在群体药代动力学中的评估。
J Biopharm Stat. 1995 Jul;5(2):141-58. doi: 10.1080/10543409508835104.
8
[Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment].
Bull Cancer. 1996 Aug;83(8):664-76.
9
[Bayesian estimation of pharmacokinetic parameters of etoposide].[依托泊苷药代动力学参数的贝叶斯估计]
Bull Cancer. 1997 Jul;84(7):699-703.
10
Population pharmacokinetic analysis of amikacin and validation on neonates using Monte Carlo method.阿米卡星的群体药代动力学分析及基于蒙特卡洛法的新生儿验证
Acta Pharmacol Sin. 2000 Oct;21(10):954-60.

引用本文的文献

1
A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.一种优化初始药物剂量和达到目标暴露区间的非参数方法:概念及在儿科白消安中的应用
Clin Pharmacokinet. 2017 Apr;56(4):435-447. doi: 10.1007/s40262-016-0448-6.
2
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.复杂药代动力学和药效学模型的群体分析方法及软件综述,并附实例
AAPS J. 2007 Mar 2;9(1):E60-83. doi: 10.1208/aapsj0901007.
3
Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
雷替曲塞在晚期实体瘤患者中的群体药代动力学。
Br J Clin Pharmacol. 2004 Apr;57(4):416-26. doi: 10.1111/j.1365-2125.2003.02050.x.
4
Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.多西他赛每周给药在晚期癌症患者中的群体药代动力学
Br J Clin Pharmacol. 2004 Jan;57(1):44-53. doi: 10.1046/j.1365-2125.2003.01956.x.
5
Individualised dosing strategy for high-dose carboplatin in patients with germ cell cancer.生殖细胞癌患者高剂量卡铂的个体化给药策略
Br J Cancer. 2003 Sep 1;89(5):787-94. doi: 10.1038/sj.bjc.6601215.
6
Caffeine in apnoeic Asian neonates: a sparse data analysis.呼吸暂停亚洲新生儿中的咖啡因:一项稀疏数据分析。
Br J Clin Pharmacol. 2002 Jul;54(1):31-7. doi: 10.1046/j.1365-2125.2002.01589.x.
7
In silico prediction of optimal in vivo delivery properties using convolution-based model and clinical trial simulation.
Pharm Res. 2002 Jan;19(1):99-103. doi: 10.1023/a:1013667718695.
8
Population pharmacokinetics of amphotericin B in children with malignant diseases.两性霉素B在患有恶性疾病儿童中的群体药代动力学。
Br J Clin Pharmacol. 2001 Dec;52(6):671-80. doi: 10.1046/j.0306-5251.2001.01496.x.
9
Population pharmacokinetics and pharmacodynamics of oral etoposide.口服依托泊苷的群体药代动力学与药效学
Br J Clin Pharmacol. 2001 Nov;52(5):511-9. doi: 10.1046/j.0306-5251.2001.01468.x.
10
Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis.环丙沙星在人眼中的药代动力学:一项临床研究及群体药代动力学分析。
Antimicrob Agents Chemother. 2000 Jun;44(6):1674-9. doi: 10.1128/AAC.44.6.1674-1679.2000.